Brainstorm cell therapeutics submits type a meeting request to u.s. food and drug administration

Meeting expected to occur within 30 days of the fda's receipt of the meeting request new york , dec. 12, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the company has submitted a type a meeting request to the u.s. food and drug administration (fda) to discuss the contents of a refusal to file letter previously issued by the fda regarding the company's new biologics license application (bla) for nurown® for the treatment of als. the type a meeting is expected to occur within 30 days of the fda's receipt of the meeting request.
BCLI Ratings Summary
BCLI Quant Ranking